On September 27, 2023 Affimed N.V. (Nasdaq: AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that an abstract with a comparison of NK cell redirected by the Company’s innate cell engagers (ICE) versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), which will be held on November 1-5, 2023 in San Diego, California (Press release, Affimed, SEP 27, 2023, https://www.affimed.com/affimed-announces-acceptance-of-an-abstract-comparing-nk-cells-redirected-by-innate-cell-engagers-and-car-nk-cells-for-poster-presentation-at-the-38th-annual-meeting-of-the-society-for-immunotherapy-o/ [SID1234635464]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Title: Redirecting NK cell cytotoxicity by Innate Cell Engagers: A differentiated and innovative approach compared to CAR-NK cells
Presenting Author: Sonya Ioana Ciulean
Abstract Number: 329
Poster Presentation Time: Friday, Nov. 3, 2023, 12:00 – 1:30 p.m. and 5:10 – 6:40 p.m.
Location: Exhibit Halls A and B1 – San Diego Convention Center
More details about the SITC (Free SITC Whitepaper) conference are available online at Home – SITC (Free SITC Whitepaper) 2023 (sitcancer.org).